• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by Fortrea Holdings Inc.

    6/12/25 9:12:27 AM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email
    8-A12B 1 d52825d8a12b.htm 8-A12B 8-A12B
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-A

     

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR 12(g) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

     

    Fortrea Holdings Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-41704   92-2796441
    (State or other jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

     

    Durham,  

    8 Moore Drive

    North Carolina

      27709
    (Address of principal executive offices)   (Zip Code)

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    to be so registered

     

    Name of each exchange on which

    each class is to be registered

    Preferred Stock Purchase Rights   The Nasdaq Stock Market LLC

     

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

    Securities Act registration statement file number to which this form relates (if applicable):

    Not applicable.

    Securities to be registered pursuant to Section 12(g) of the Act:

    None.

    N/A

    (Title of class)

     

     
     


    Item 1. Description of Registrant’s Securities to be Registered.

    On June 11, 2025, the Board of Directors of Fortrea Holdings Inc. (the “Company”) declared a dividend of one preferred share purchase right (a “Right”) for each share of common stock, par value $0.001 per share, of the Company (the “Common Shares”) outstanding on June 23, 2025 to the stockholders of record on that date. In connection with the distribution of the Rights, the Company entered into a Rights Agreement (the “Rights Agreement”), dated as of June 11, 2025, between the Company and Equiniti Trust Company, LLC, as rights agent.

    Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series A Preferred Stock, par value $0.001 per share, of the Company (the “Preferred Shares”) at a price of $50.00 per one one-thousandth of a Preferred Share represented by a Right (the “Purchase Price”), subject to adjustment.

    The Rights are in all respects subject to and governed by the provisions of the Rights Agreement, which is incorporated herein by reference. The description of the Rights is incorporated herein by reference to the description set forth under Items 1.01 and 5.03 of the Company’s Current Report on Form 8-K filed on June 12, 2025 and is qualified in its entirety by reference to the full text of the Rights Agreement.

    Item 2. Exhibits.

     

    Exhibit No.

      

    Description

     3.1    Certificate of Designations of Series A Preferred Stock of Fortrea Holdings Inc., as filed with the Secretary of State of the State of Delaware on June 12, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 12, 2025).
     4.1    Rights Agreement, dated as of June  11, 2025, between Fortrea Holdings Inc. and Equiniti Trust Company, LLC, as rights agent (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on June  12, 2025).
    99.1    Press Release, dated June 12, 2025 (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed on June 12, 2025)


    SIGNATURE

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

     

    Fortrea Holdings Inc.
    By:   /s/ Stillman Hanson
      Name: Stillman Hanson
      Title: General Counsel and Secretary

    Date: June 12, 2025

    Get the next $FTRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    1/8/2026$22.00Hold → Buy
    Truist
    1/6/2026$25.00In-line → Outperform
    Evercore ISI
    12/15/2025$15.00Underweight → Equal Weight
    Barclays
    12/11/2025$21.00Neutral → Buy
    Citigroup
    8/4/2025$9.00Neutral → Outperform
    Robert W. Baird
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    12/11/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    More analyst ratings

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call

    DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following ea

    1/29/26 8:08:01 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference

    DURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, January 13, 2026, at the J.P. Morgan Annual Healthcare Conference (San Francisco). CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the conference. The live webcast and replay can be accessed through the "Events" section of Fortrea's  Investor Relations website. Investors interested in one-on-one meetings should contact their banking representatives. About Fortrea Fortrea (NASDAQ:FTRE) is a leading global provider of clinical development

    1/9/26 11:24:21 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference

    DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference in January: J.P. Morgan Annual Healthcare Conference (San Francisco)Date:Tuesday, January 13, 2025Time:5:15 pm PSTFormat:Presentation and Q&A   The live webcast and replay can be accessed through the "Events" section of Fortrea's Investor Relations website. Investors interested in one-on-one meetings should contact their banking representatives. About FortreaFortrea (NASDAQ:FTRE) is a leading global provider of clinic

    1/6/26 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by Truist with a new price target

    Truist upgraded Fortrea from Hold to Buy and set a new price target of $22.00

    1/8/26 8:10:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Fortrea from In-line to Outperform and set a new price target of $25.00

    1/6/26 8:26:05 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Barclays with a new price target

    Barclays upgraded Fortrea from Underweight to Equal Weight and set a new price target of $15.00

    12/15/25 9:05:06 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    SEC Filings

    View All

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 144 filed by Fortrea Holdings Inc.

    144 - Fortrea Holdings Inc. (0001965040) (Subject)

    1/20/26 3:30:32 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    11/20/25 4:11:54 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fortrea Holdings Inc.

    SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

    11/14/25 11:22:58 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Chief Operating Officer Morais Mark A. converted options into 2,255 shares and sold $16,365 worth of shares (1,179 units at $13.88), increasing direct ownership by 2% to 58,052 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    2/11/26 7:04:31 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Chief Financial Officer Mcconnell Jill G. sold $12,229 worth of shares (881 units at $13.88) and converted options into 1,685 shares, increasing direct ownership by 1% to 59,574 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    2/11/26 7:02:25 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Sharbaugh William J

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    11/24/25 4:03:48 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Russell Erin L bought $100,018 worth of shares (9,854 units at $10.15) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/4/25 4:39:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Neupert Peter M bought $407,150 worth of shares (62,500 units at $6.51), increasing direct ownership by 175% to 98,132 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    8/11/25 8:21:29 PM ET
    $FTRE
    Medical Specialities
    Health Care

    General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/24 6:28:42 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Financials

    Live finance-specific insights

    View All

    Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call

    DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following ea

    1/29/26 8:08:01 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Reports Third Quarter 2025 Results

    For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 millionGAAP net loss of $(15.9) millionAdjusted EBITDA of $50.7 millionGAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectivelyBook-to-bill ratio of 1.13x, resulting in 1.07x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,700 million to $2,750 million; narrowing 2025 adjusted EBITDA guidance to a range of $175 million to $195 million DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported

    11/5/25 6:30:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call

    DURHAM, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast

    10/15/25 7:00:24 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    Fortrea Appoints Agnieszka Gallagher as General Counsel

    DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company's legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea's leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period. "Aggie brings broad and deep executive experience in the life sciences and beyond to Fortrea, with a track record of navigating complexity in global companies," said Anshul Thakral, CEO of Fortrea.

    11/17/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints William Sharbaugh to Board of Directors

    DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company's Board of Directors. Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry. "I'm delighted to welcome Bill to the Fortrea Board, bringing an impressive background in CRO and pharmaceutical operations," said Anshul Thakral, CEO of Fortrea. "He is a highly respected leader, who understands our stakeholders a

    9/22/25 4:30:50 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

    DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. "Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter," said McConnell. "She brings not only deep capital markets expertise but also integrity, insi

    8/5/25 6:00:02 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortrea Holdings Inc.

    SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

    11/12/24 9:55:14 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    5/28/24 5:10:47 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    2/26/24 7:01:18 PM ET
    $FTRE
    Medical Specialities
    Health Care